Urethra Carcinoma clinical trials at UC Health
1 research study open to new patients

• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

  open to eligible people ages 18 years and up

  The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.

  at UCLA UCSD

Last updated: February 5, 2019